PTC Therapeutics Inc. diskutieren
PTC Therapeutics Inc.
WKN: A1W0MW / Symbol: PTCT / Name: PTC Therapeutics / Aktie / Biotechnologie & medizinische Forschung / Mid Cap /
31,00 €
-4,91 %
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its price target raised by analysts at JPMorgan Chase & Co. from $43.00 to $53.00. They now have an "overweight" rating on the stock.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its price target raised by analysts at Citigroup Inc. from $18.00 to $26.00. They now have a "sell" rating on the stock.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $18.00 to $32.00. They now have a "sell" rating on the stock.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its "overweight" rating re-affirmed by analysts at JPMorgan Chase & Co.. They now have a $53.00 price target on the stock.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its price target raised by analysts at Bank of America Co. from $25.00 to $32.00. They now have an "underperform" rating on the stock.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its price target raised by analysts at Cantor Fitzgerald from $52.00 to $62.00. They now have an "overweight" rating on the stock.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its price target raised by analysts at Cantor Fitzgerald from $62.00 to $64.00. They now have an "overweight" rating on the stock.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $64.00 price target on the stock.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics, Inc. (NASDAQ: PTCT) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $47.00 price target on the stock.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics, Inc. (NASDAQ: PTCT) is now covered by analysts at Robert W. Baird. They set an "outperform" rating and a $44.00 price target on the stock.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics, Inc. (NASDAQ: PTCT) was upgraded by analysts at Baird R W to a "strong-buy" rating.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $64.00 price target on the stock.
Ratings data for PTCT provided by MarketBeat
Neueste Beiträge
StockNews_com in Quaker Chemical Corp. diskutieren